Clinical Research Directory

Inclusion Criteria: * HIV-1 infection, coinfection HIV-1/HIV-2 possible * Age≥18 years old * Current therapy unchanged for the last 4 months * Receiving tritherapy with 2 nucleoside reverse transcriptase inhibitor+protease inhibitors or 2 nucleoside reverse transcriptase inhibitor+non-nucleoside reverse transcriptase inhibitors or 2 nucleoside reverse transcriptase inhibitor+integrase inhibitors. Allowed treatment drugs are : 1\. nucleoside analogs : tenofovir (TDF ou TAF), emtricitabine, abacavir, lamivudine 2. protease inhibitors : lopinavir/r, darunavir/r ou atazanavir/r 3. Non nucleoside reverse transcriptase inhibitors : efavirenz, rilpivirine ou etravirine 4. integrase inhibitors : dolutegravir, elvitegravir/cobicistat ou raltegravir * Viruses susceptible to all antiretroviral drugs present in the ongoing tritherapy (AC11-ANRS algorithm). 1. If a genotype is available in the patient medical history; viruses must be susceptible to all ongoing antiretroviral drugs 2. If no RNA genotype available, a genotype will be performed on DNA at screening and will not have to show any resistance to the ongoing antiretroviral drugs * Viral load (VL) \< 50 cp/mL in the past year, with at least 3 VL measurements including screening; only one episode of viral blip \< 200 copies/mL is authorized in the last year * CD4 T cells \> 250/mm3 at the screening visit * Estimated glomerular filtration rate \> 60 mL/min (Chronic Kidney Disease - Epidemiology Collaboration method) * Transaminases : aspartate aminotransférase et alanine aminotransférase \< 3N * Haemoglobin \> 10 g/dL * Platelets \> 100 000/mm3 * For women of childbearing age, negative pregnancy test at screening; agree to use mechanical contraception during the study * Social security system coverage * Informed consent form signed by patient and investigator Exclusion Criteria: * Infection by HIV-2 * Chronic and active Viral B Hepatitis with positive antigen HBs * Chronic and active Viral C Hepatitis with treatment expected in the next 98 weeks * Concomitant treatment using interferon, interleukins, any other immune-therapy or chemotherapy, antivitaminK for patients on ARVT using a booster * Concomitant prophylactic or curative treatment for an opportunistic infection * All conditions (use of alcohol, drugs, etc.) judged by the investigator to possibly interfere with study protocol compliance, observance and/or study treatment tolerance * Pregnant or breast feeding women * Subjects under "sauvegarde de justice" (judicial protection due to temporarily and slightly diminished mental or physical faculties), or under legal guardianship